XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 100.01

Change

-0.50 (-0.50)%

Market Cap

N/A

Volume

8.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.39 (-0.26%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-0.27 (-0.38%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-0.07 (-0.06%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.55 (-1.68%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.24 (-0.97%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-0.53 (-1.31%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-1.07 (-1.10%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.09 (-0.29%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-1.84%)

USD 0.01B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

-0.05 (0%)

USD 0.05B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.01% 71% C- 59% D-
Dividend Return 0.15% 19% F 2% F
Total Return 12.15% 71% C- 52% F
Trailing 12 Months  
Capital Gain 40.66% 90% A- 85% B
Dividend Return 0.20% 17% F 2% F
Total Return 40.86% 90% A- 83% B
Trailing 5 Years  
Capital Gain 17.95% 29% F 56% F
Dividend Return 0.55% 28% F 2% F
Total Return 18.50% 29% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain -0.08% 19% F 32% F
Dividend Return -0.01% 24% F 22% F
Total Return 0.08% 26% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 33.03% 19% F 32% F
Risk Adjusted Return -0.02% 24% F 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.